Trial Profile

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2-positive Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anbenitamab (Primary) ; Docetaxel (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Sponsors Jiangsu Alphamab Biopharmaceuticals

24 Oct 2023 Status changed to completed, Results presented at the 48th European Society for Medical Oncology Congress
24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
10 Dec 2022 Preliminary results (at data cut-off: 15 April 2022; n=15) assessing KN026 and docetaxel as neoadjuvant treatment in patients with HER2-positive early or locally advanced breast cancer, presented at the 45th Annual San Antonio Breast Cancer Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com